The finding is significant because anti-PD-1 drugs do not work uniformly across gastric cancers. These medicines are immune checkpoint inhibitors, designed to release a molecular brake imposed by the PD-1 pathway. PD-1 is a receptor found primarily on activated T cells, while its ligands, including PD-L1, can be displayed by tumor cells or other cells in the tumor microenvironment. When PD-1 binds its ligand, T-cell signaling is dampened, limiting the immune attack. Blocking that interaction can restore T-cell activity, but only when the surrounding immune ecosystem is capable of mounting a meaningful response.

HER2-positive gastric cancer is defined by increased activity of the human epidermal growth factor receptor 2, a protein involved in cell growth and survival. HER2-targeted therapies have transformed treatment for some patients, yet resistance and disease progression remain common. The new work places vitamin B5, also known as pantothenic acid, in this therapeutic landscape. Vitamin B5 is traditionally recognized as a precursor of coenzyme A, a central metabolic molecule required for fatty-acid synthesis and breakdown, energy production, and the modification of proteins. The study suggests that its influence may extend beyond basic nutrition into the immune biology of cancer.

Rather than acting simply as a fuel, vitamin B5 appears to support the cellular conditions needed for an effective response to PD-1 blockade. The reported association is especially intriguing because immune cells undergo major metabolic changes when they become activated. T cells need energy and biosynthetic materials to proliferate, produce cytokines, and maintain their attack on malignant cells. B cells also depend on carefully regulated metabolic programs as they transition from a resting state into antibody-producing or antigen-presenting populations. A nutrient connected to coenzyme A metabolism could therefore affect how immune cells communicate and function inside a tumor.

The study highlights an interaction between naïve B cells and T cells. Naïve B cells are mature lymphocytes that have not yet encountered, or been fully activated by, their specific antigen. They are not immunologically inactive; under the right signals, they can capture antigen, present peptide fragments on major histocompatibility complex class II molecules, and provide additional stimulatory cues to T cells. This makes them potential organizers of antitumor immunity rather than passive bystanders. According to the research, vitamin B5 enhances the interaction between these naïve B cells and T cells, creating a cellular dialogue that may reinforce the response unleashed by anti-PD-1 treatment.

That dialogue matters because successful checkpoint therapy depends on more than the presence of exhausted T cells. T cells must recognize tumor-derived antigens, receive appropriate costimulatory signals, and remain supported by neighboring immune populations. B cells can contribute to this process by presenting antigens, producing immune-regulating molecules, and helping shape organized lymphocyte responses. When B-cell and T-cell communication is strengthened, tumor antigens may be more effectively introduced to the adaptive immune system, potentially expanding the pool of T cells capable of recognizing cancer cells.

The findings also add to a growing scientific shift toward studying cancer metabolism and the tumor microenvironment together. Cancer cells compete with immune cells for nutrients, while local conditions such as oxygen deprivation, acidity, and abnormal metabolite concentrations can suppress immune function. A dietary compound or metabolic cofactor may have different effects depending on which cells can access it and how they process it. Vitamin B5 could influence the balance between malignant cells and immune populations through coenzyme A-dependent pathways, although the precise molecular steps linking supplementation or availability to immune activation will require further investigation.

Importantly, the research does not mean that vitamin B5 is established as a standalone cancer treatment or that patients should self-administer high doses alongside immunotherapy. Nutrients can have context-dependent effects, and immune checkpoint inhibitors can cause serious inflammatory side effects when activated T cells attack healthy tissues. The clinical relevance of the findings will depend on validation in additional experimental systems and, ultimately, carefully designed clinical trials that establish dose, safety, patient selection, and treatment timing. It will also be necessary to determine whether the effect is specific to HER2-positive gastric cancer or applies to other tumor types and molecular subgroups.

The study nevertheless offers a compelling therapeutic concept: improving immunotherapy may involve not only blocking inhibitory receptors such as PD-1, but also nourishing and coordinating the immune networks that make checkpoint release effective. By connecting vitamin B5 metabolism with B-cell–T-cell communication, the researchers provide a possible explanation for why some tumors respond more strongly than others to anti-PD-1 therapy. If future work confirms the mechanism, vitamin B5-related metabolic signatures could help identify patients most likely to benefit, while nutritional or pharmacological strategies might be developed to support immune activation. For now, the research turns an ordinary vitamin into an unexpected lead in the search for more durable responses against HER2-positive gastric cancer.

Subject of Research: Vitamin B5, anti-PD-1 immunotherapy, HER2-positive gastric cancer, and interactions between naïve B cells and T cells.

Article Title: Vitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between naïve B cells and T cells.

Article References: Wang, C., Yang, J., Lai, MY. et al. “Vitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between naïve B cells and T cells.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76239-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76239-3

Keywords: Vitamin B5, pantothenic acid, anti-PD-1, immunotherapy, HER2-positive gastric cancer, naïve B cells, T cells, tumor microenvironment, cancer metabolism.

Melanoma represents a particularly aggressive skin cancer subtype with a notorious ability to evade immune surveillance. While immunotherapy has revolutionized treatment paradigms by harnessing the body’s immune defenses, many tumors evolve mechanisms to subvert immune attack, rendering therapy ineffective. The study focuses on elucidating the molecular underpinnings of immune evasion, with DHHC3 emerging as a critical player influencing melanoma’s immunological landscape.

DHHC3 functions as a palmitoyltransferase, an enzyme catalyzing the attachment of palmitoyl groups to target proteins, thus affecting their localization, stability, and function. Additionally, DHHC3 is known to moderate oxidative stress by maintaining cellular redox homeostasis. Prior studies hinted at correlations between elevated DHHC3 expression and poor clinical outcomes across several cancer types, prompting investigation into its specific role within melanoma microenvironments.

Utilizing CRISPR-Cas9 gene editing, the team ablated DHHC3 expression in the murine B16F10 melanoma cell line, creating a model to observe resultant cellular and immunological changes. Loss of DHHC3 induced pronounced oxidative stress within tumor cells, evidenced by an upregulation of TXNIP, a potent mediator of reactive oxygen species. This heightened oxidative stress triggered senescence-associated pathways, marked by increased expression of classical senescence markers, indicating that DHHC3 ablation compromises tumor cell homeostasis.

Crucially, when these DHHC3-deficient melanoma cells were implanted into immunocompetent mice, tumor growth was substantially diminished compared to controls. Interestingly, this growth suppression was absent in immunodeficient mice lacking functional immune systems, pointing toward an immune-dependent mechanism underlying the observed tumor inhibition. The results suggest that DHHC3 enables melanoma cells to escape immune recognition, and its loss reinvigorates host anti-tumor immunity.

Immune profiling of the tumor microenvironment revealed significant shifts in immune cell populations following DHHC3 knockout. Tumors exhibited marked infiltration by natural killer (NK) cells, M1-polarized macrophages associated with pro-inflammatory and anti-tumor functions, as well as CD4+ and CD8+ T lymphocytes, all instrumental in orchestrating effective immune responses against malignancies. Conversely, populations of immunosuppressive M2 macrophages and myeloid-derived suppressor cells (MDSCs), which typically promote tumor progression, were reduced.

Despite these profound changes in primary tumor growth dynamics, pulmonary metastases did not show significant differences between DHHC3-expressing and knockout conditions in either immunocompetent or immunodeficient mice. Additionally, melanoma cell proliferation rates measured under traditional culture conditions remained unchanged, underscoring that DHHC3’s impact is not due to intrinsic growth alterations but rather through modulating immune interactions in vivo.

The researchers propose a model whereby increased oxidative stress and cellular senescence triggered by DHHC3 deficiency elicit a senescence-associated secretory phenotype (SASP). This SASP acts as a molecular beacon, recruiting and activating anti-tumor immune effector cells into the tumor microenvironment, enhancing immune-mediated tumor clearance. Such a mechanism highlights the dual role of DHHC3 in both cellular homeostasis and immune regulation within melanoma.

These findings illuminate DHHC3 as a multifunctional regulator that melanoma cells exploit to evade immune surveillance, thereby facilitating tumor survival and expansion. Targeting DHHC3 enzymatic activity or its downstream signaling pathways may represent an innovative therapeutic avenue to bolster anti-melanoma immunity, particularly in tumors refractory to existing immunotherapies.

Beyond its immediate implications for melanoma treatment, the study also provides valuable insight into the intricate crosstalk between oxidative stress, cellular senescence, and immune modulation. It sets the stage for future investigations aimed at exploiting metabolic and immunological vulnerabilities in cancer.

In conclusion, the research narrates a compelling story positioning DHHC3 as a central node linking tumor-intrinsic oxidative regulation to extrinsic immune environment alterations. The strategic targeting of DHHC3 could enhance the efficacy of immunotherapeutic regimens and mitigate immune escape, offering renewed hope for melanoma patients facing poor prognoses.

This study stands as a testament to the power of combining advanced gene editing techniques with robust in vivo models to unravel cancer’s evasive tactics, paving the way for next-generation immunomodulatory therapies.

Subject of Research: Cells
Article Title: DHHC3 interferes with antitumor immunity in melanoma cells
News Publication Date: June 8, 2026
Web References: https://doi.org/10.18632/oncotarget.28880
Image Credits: Copyright: © 2026 Sharma et al. (Distributed under CC BY 4.0 license)
Keywords: cancer, oxidative stress, DHHC3, anti-cancer immunity, palmitoylation, melanoma

Cancer cells have evolved numerous methods for evading the immune response, and the secretion of extracellular vesicles represents one of the most cunning. These vesicles, which can include exosomes and microvesicles, are released into the tumor microenvironment and the systemic circulation, acting as messengers that impact distant and proximate cells alike. Zeng and colleagues highlight how these vesicles carry a cargo rich in proteins, lipids, and genetic material, which play pivotal roles in modifying immune responses and promoting a supportive environment for tumor growth.

One of the critical aspects of tumor-derived extracellular vesicles is their ability to alter the metabolic landscape of immune cells. Zeng et al. provide compelling evidence that these vesicles can induce a shift in the metabolism of T cells and macrophages—key players in anti-tumor immunity. This reprogramming leads to what some researchers have termed an “immunosuppressive phenotype,” which compromises the ability of immune cells to recognize and attack tumor cells effectively. By hijacking these metabolic pathways, tumors can effectively shield themselves from immune surveillance.

Furthermore, another layer of complexity is added by the notion that tumor-derived EVs can influence not just immune cells but also the endothelial cells that line blood vessels in the tumor microenvironment. The study demonstrates that these vesicles can enhance angiogenesis, the process by which new blood vessels form from existing ones. This is crucial for tumors, which depend on a robust vascular supply to thrive and metastasize. The modulation of endothelial cell metabolism by tumor-derived EVs exemplifies the multifaceted nature of the tumor-immune interface.

Another striking finding from Zeng et al. is the connection between extracellular vesicles and the development of resistance to immunotherapy. Cancer immunotherapy, while having revolutionized the treatment landscape for many malignancies, is not universally effective. The presence of tumor-derived EVs has been shown to correlate with poorer outcomes in patients undergoing such therapies, suggesting that these vesicles may contribute to treatment failure. The study reveals that by downregulating immune checkpoint markers and influencing various signaling pathways involved in immune activation, EVs can create an environment resistant to the effects of therapeutic agents.

Zeng and colleagues also introduce new potential therapeutic strategies that could harness this knowledge. Developing specific inhibitors or modifiers of extracellular vesicle function could improve the efficacy of existing immunotherapies. Moreover, the study proposes the idea of engineering EVs to carry therapeutic agents or immune modulators to re-educate T cells and other immune components. The clinical implications of these potential interventions could be profound, paving the way for more successful outcomes in cancer treatment.

Another fascinating angle explored in the study pertains to the hands of the tumor microenvironment—how it not only serves as a battlefield for immune and cancerous cells but also actively reshapes the immune landscape over time. Zeng et al. discuss the temporal dynamics of EV release in relation to tumor progression and treatment responses. This insight could lead to the development of biomarkers that help predict tumor behavior and responsiveness to therapies.

In addition, the researchers underline the need for a deeper understanding of the molecular constituents of tumor-derived EVs. The proteins, lipids, and RNA molecules carried in these vesicles often reflect the state of their parent tumor cells, making them potential biomarkers for diagnosis and prognosis. Zeng et al.’s work encourages a comprehensive analysis of the vesicular cargo to derive better insights into the tumor’s behavior and the immune landscape.

One cannot overlook the implications of this research on the personalized medicine front. The individual variability in EV profiles could inform tailored therapeutic strategies that consider a patient’s unique tumor environment and immune makeup. This could herald a transformative approach in oncology, moving away from a one-size-fits-all regimen to more nuanced, patient-specific therapies that enhance treatment efficacy while reducing adverse effects.

While the study’s findings are exciting, they also unveil a plethora of questions that demand further investigation. The specific mechanisms through which EVs mediate their effects on immune cells vary widely and are still not completely understood. Future research must aim to delineate these pathways, distinguishing between pro- and anti-tumor functions of different populations of EVs under various conditions. This understanding will be critical for designing rational therapeutic interventions.

Understanding the role of EVs in tumor biology also sheds light on the broader implications of cancer treatment in the context of other chronic diseases. As research in immunometabolism burgeons, the parallels between cancer and other conditions such as autoimmune diseases, obesity, and metabolic syndrome could illustrate fundamental biological processes governed by extracellular vesicles. Zeng et al.’s work is a pioneering step in bridging these fields and fostering a cohesive dialogue between cancer researchers and specialists in other areas of medicine.

As this area of research grows, multidisciplinary collaboration will be essential. The interplay of cancer biology, immunology, biochemistry, and clinical medicine highlights the complexity of developing effective treatment strategies. The work of Zeng et al. serves as a call to action for the scientific community to unify efforts, combining expertise from diverse fields to tackle the challenges posed by tumor-derived extracellular vesicles.

In conclusion, the study by Zeng and colleagues culminates in a significant advancement in our understanding of how tumor-derived extracellular vesicles alter immune responses and contribute to therapeutic resistance. By offering insights into these underlying mechanisms, the authors not only pave the way for innovative approaches to combat cancer but also challenge researchers to frame the ongoing narrative of cancer treatment in light of the evolving dynamics of the immune system. The potential for harnessing this knowledge to develop targeted therapies illuminates a hopeful path forward in the fight against cancer.

Subject of Research: Tumor-derived extracellular vesicles and their role in immunometabolic reprogramming and immunotherapeutic resistance.

Article Title: Mechanisms of tumor-derived extracellular vesicle-mediated immunometabolic reprogramming and immunotherapeutic resistance.

Article References:

Zeng, H., Zhang, R., Zhu, X. et al. Mechanisms of tumor-derived extracellular vesicle-mediated immunometabolic reprogramming and immunotherapeutic resistance.
Mol Cancer (2026). https://doi.org/10.1186/s12943-025-02556-8

Image Credits: AI Generated

DOI: 10.1186/s12943-025-02556-8

Keywords: extracellular vesicles, tumor biology, immunometabolism, immunotherapy resistance, cancer treatment, immune cell reprogramming, therapeutic strategies.